New hope for lymphoma patients as trial tests powerful drug combo

NCT ID NCT04077723

Ongoing Disease control Sponsor: Hoffmann-La Roche Source: ClinicalTrials.gov ↗

Summary

This study is testing a new drug called englumafusp alfa, given with other approved lymphoma drugs, for people whose Non-Hodgkin's lymphoma has come back or hasn't responded to previous treatments. The main goals are to find a safe dose and see if the combination can shrink tumors. It is enrolling about 500 participants who have limited treatment options left.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Locations

Aarhus Universitetshospital Skejby

Aarhus N, 8200, Denmark
Asan Medical Center

Seoul, 05505, South Korea
Asst Papa Giovanni Xxiii

Bergamo, Lombardy, 24127, Italy
Auckland City Hospital, Cancer and Blood Research

Auckland, 1023, New Zealand
Beijing Cancer Hospital

Beijing, 100142, China
Beth Israel Medical Center

Boston, Massachusetts, 02215, United States
CHRU de Lille

Lille, 59037, France
CHU DE RENNES - CHU Pontchaillou

Rennes, 35033, France
CHU Montpellier - Saint ELOI

Montpellier, 34295, France
Centre Hospitalier Lyon Sud

Pierre-Bénite, 69495, France
City of Hope Medical Center

Pasadena, California, 91105, United States
Clinica Universidad de Navarra Madrid

Madrid, 28027, Spain
Clinica Universitaria de Navarra

Pamplona, Navarre, 31008, Spain
Colorado Blood Cancer Institute (CBCI) at Presbyterian/ St. Luke's Medical Center

Denver, Colorado, 80218, United States
Fudan University Shanghai Cancer Center

Shanghai, 201315, China
Hospital Clinico Universitario Virgen de la Victoria

Málaga, 29010, Spain
Hospital Duran i Reynals L'Hospitalet

L'Hospitalet de Llobregat, Barcelona, 08908, Spain
Hospital Univ. 12 de Octubre

Madrid, 28041, Spain
Hospital Universitari Vall d'Hebron

Barcelona, 08035, Spain
Irccs Istituto Europeo Di Oncologia (IEO)

Milan, Lombardy, 20141, Italy
Istituto Clinico Humanitas

Rozzano, Lombardy, 20089, Italy
Istituto Nazionale Tumori Irccs Fondazione g. Pascale

Napoli, Campania, 80131, Italy
Jewish General Hospital

Montreal, Quebec, H3T 1E2, Canada
MSKCC

New York, New York, 10065, United States
Odense Universitetshospital

Odense C, 5000, Denmark
OhioHealth Research Institute

Columbus, Ohio, 43221-2417, United States
Peter Maccallum Cancer Centre

Melbourne, Victoria, 3000, Australia
Pusan National University Hospital

Busan, 49241, South Korea
Queen Elizabeth II Health Sciences Centre

Halifax, Nova Scotia, B3H 2Y9, Canada
Rigshospitalet

København Ø, 2100, Denmark
SCRI Oncology Partners

Nashville, Tennessee, 37203, United States
Samsung Medical Center

Seoul, 06351, South Korea
Seoul National University Hospital

Seoul, 03080, South Korea
Shandong Cancer Hospital

Jinan, 250117, China
South Austin Medical Center

Austin, Texas, 78704, United States
The Alfred Hospital

Melbourne, Victoria, 3004, Australia
The First Affiliated Hospital of Xiamen University

Xiamen, 361003, China
The HOPE Clinical Trials Unit

Leicester, LE1 5WW, United Kingdom
The University of Texas MD Anderson Cancer Center

Houston, Texas, 77030-4009, United States
UZ Gent

Ghent, 9000, Belgium
University College London Hospitals NHS Foundation Trust

London, W1T 7HA, United Kingdom
University of California San Francisco

San Francisco, California, 94158, United States
Waikato Hospital - Cancer and Blood Research Trials Unit

Hamilton, 3204, New Zealand
Washington University School of Medicine

St Louis, Missouri, 63110, United States

Conditions

Explore the condition pages connected to this study.

LYMPHOMA, NON-HODGKIN